Citation: Xiaofang Luo, Ye Wu, Xiaokun Zhang, Min Tang, Feiye Ju, Zuodong Qin, Gregory J Duns, Wei-Dong Zhang, Jiang-Jiang Qin, Xin Luan. Peptide-based strategies for overcoming multidrug-resistance in cancer therapy[J]. Chinese Chemical Letters, ;2025, 36(1): 109724. doi: 10.1016/j.cclet.2024.109724 shu

Peptide-based strategies for overcoming multidrug-resistance in cancer therapy

Xiaofang Luo ^{a, 1} ,
Ye Wu ^{b, 1} ,
Xiaokun Zhang ^{b, 1} ,
Min Tang ^b ,
Feiye Ju ^a ,
Zuodong Qin ^a ,
Gregory J Duns ^a ,
Wei-Dong Zhang ^{b, d, *,} ,
Jiang-Jiang Qin ^{c, *,} ,
Xin Luan ^{b, *,}

a.
Hunan Engineering Technology Research Center for Comprehensive Development and Utilization of Biomass Resources, College of Chemistry and Bioengineering, Hunan University of Science and Engineering, Yongzhou 425199, China
b.
Shanghai Frontiers Science Center of TCM Chemical Biology, Institute of Interdisciplinary Integrative Medicine Research and Shuguang Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China
c.
Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou 310022, China
d.
State Key Laboratory for Quality Ensurance and Sustainable Use of Dao-di Herbs, Institute of Medicinal Plant Development, Chinese Academy of Medical Science and Peking Union Medical College, Beijing 100700, China

wdzhangy@hotmail.com

jqin@ucas.ac.cn

luanxin@shutcm.edu.cn

Received Date: 15 January 2024
Revised Date: 27 February 2024
Accepted Date: 29 February 2024
Available Online: 7 March 2024

Figures(2)

Despite ongoing advancements in cancer treatment, the emergence of primary and acquired resistance poses a significant challenge for both traditional chemotherapy and immune checkpoint blockade therapies. The demand for targeted therapeutics for multidrug-resistant cancer is more important than ever. Peptides, as emerging alternatives to current anticancer drugs, offer exquisite versatility in facilitating the design of novel oncology drugs, with the core superiorities of good biocompatibility and a low tendency to induce drug resistance. This review comprehensively introduces the pharmacological mechanisms of peptide-based drugs and strategies for overcoming multidrug resistance (MDR) in cancers, including inducing cell membrane lysis, targeting organelles, activating anticancer immune responses, enhancing drug uptake, targeting ATP-binding cassette (ABC) transporters, and targeting B-cell lymphoma-2 (BCL-2) family proteins. Additionally, the current clinical applications of representative peptides in combating MDR cancers and their potential directions for medicinal chemistry research have been thoroughly discussed. This review offers essential insights into the novel treatment approaches for MDR cancers and highlights the trends and perspectives in this field.
- Drug resistance,
- Antitumor peptides,
- Mechanism of action,
- Targeted therapeutics,
- Immunotherapy,
- Medicinal chemistry
1. [1]
  J. Gong, T. Shi, J. Liu, et al., Biomed. Pharmacother. 161 (2023) 114505. doi: 10.1016/j.biopha.2023.114505
2. [2]
  H. Sung, J. Ferlay, R.L. Siegel, et al., CA. Cancer J. Clin. 71 (2021) 209-249. doi: 10.3322/caac.21660
3. [3]
  D. Zhu, H. Zhang, Y. Huang, et al., Pharmaceutics 13 (2021) 1092. doi: 10.3390/pharmaceutics13071092
4. [4]
  K. Pang, Z. Shi, L. Wei, et al., Drug Resist. Updat. 66 (2023) 100907. doi: 10.1016/j.drup.2022.100907
5. [5]
  B. Du, M. Zheng, H. Ma, et al., J. Nanobiotechnol. 20 (2022) 209. doi: 10.1186/s12951-022-01406-9
6. [6]
  J.Q. Wang, Y. Yang, C.Y. Cai, et al., Drug Resist. Updat. 54 (2021) 100743. doi: 10.1016/j.drup.2021.100743
7. [7]
  R. Jin, Z. Liu, T. Liu, et al., Chin. Chem. Lett. 32 (2021) 3076-3082. doi: 10.1016/j.cclet.2021.03.084
8. [8]
  Y.G. Assaraf, A. Brozovic, A.C. Goncalves, et al., Drug Resist. Updat. 46 (2019) 100645. doi: 10.1016/j.drup.2019.100645
9. [9]
  Z. Su, S. Dong, S.C. Zhao, et al., Drug Resist. Updat. 58 (2021) 100777. doi: 10.1016/j.drup.2021.100777
10. [10]
  M. Wang, W. Chen, J. Chen, et al., Eur. J. Med. Chem. 220 (2021) 113487. doi: 10.1016/j.ejmech.2021.113487
11. [11]
  Y. O. Gozde, Drug Resist. Updat. 59 (2021) 100789. doi: 10.1016/j.drup.2021.100789
12. [12]
  H. Zhang, H. Xu, C.J. Ashby, et al., Med. Res. Rev. 41 (2021) 525-555. doi: 10.1002/med.21739
13. [13]
  L. Gao, Z.X. Wu, Y.G. Assaraf, et al., Drug Resist. Updat. 57 (2021) 100770. doi: 10.1016/j.drup.2021.100770
14. [14]
  C.M. Neophytou, I.P. Trougakos, N. Erin, et al., Cancers 13 (2021) 4363. doi: 10.3390/cancers13174363
15. [15]
  M. Avitabile, F. Bonfiglio, V. Aievola, et al., Comput. Struct. Biotechnol. J. 20 (2022) 4437-4445. doi: 10.1016/j.csbj.2022.08.031
16. [16]
  E.S. Nader, A. Vito, K. Mossman, Cancers 13 (2021) 806. doi: 10.3390/cancers13040806
17. [17]
  L. Horvath, B. Thienpont, L. Zhao, et al., Mol. Cancer 19 (2020) 141. doi: 10.1556/092.2020.00111
18. [18]
  A. Saeed, R. Park, W. Sun, J. Hematol. Oncol. 14 (2021) 13. doi: 10.1186/s13045-021-01034-0
19. [19]
  B.P. Sharpe, A. Hayden, A. Manousopoulou, et al., Cell Rep. Med. 3 (2022) 100541. doi: 10.1016/j.xcrm.2022.100541
20. [20]
  H. Hu, L. Yu, Z. Ding, et al., Chin. Chem. Lett. 34 (2023) 108592. doi: 10.1016/j.cclet.2023.108592
21. [21]
  X. Luan, Y. Wu, Y.W. Shen, et al., Nat. Prod. Rep. 38 (2021) 7-17. doi: 10.1039/d0np00019a
22. [22]
  Y. Huang, H. Peng, A. Zeng, et al., Front. Pharmacol. 14 (2023) 1188477. doi: 10.3389/fphar.2023.1188477
23. [23]
  T. Haider, V. Pandey, N. Banjare, et al., Pharmacol. Rep. 72 (2020) 1125-1151. doi: 10.1007/s43440-020-00138-7
24. [24]
  T. Liu, M. Chen, J. Fu, et al., Acta Pharm. Sin. B 11 (2021) 2326-2343. doi: 10.1016/j.apsb.2021.03.003
25. [25]
  W. Shen, Y. Zhang, P. Wan, et al., Adv. Mater. 32 (2020) e2001108. doi: 10.1002/adma.202001108
26. [26]
  Y. Wu, R. Huang, J.M. Jin, et al., Front. Chem. 8 (2020) 519. doi: 10.1364/oe.380679
27. [27]
  X. Zhao, X. Li, B. Li, et al., Chem. Eng. J. 453 (2023) 139886. doi: 10.1016/j.cej.2022.139886
28. [28]
  Y. Zhang, P. He, P. Zhang, et al., Adv. Healthc. Mater. 10 (2021) e2001974. doi: 10.1002/adhm.202001974
29. [29]
  Y. Sun, H. Zhang, G. Lu, et al., Chin. Chem. Lett. 34 (2023) 107817. doi: 10.1016/j.cclet.2022.107817
30. [30]
  Q. Zhang, Z. Yan, Y. Meng, et al., Mil. Med. Res. 8 (2021) 48. doi: 10.1145/3460421.3478824
31. [31]
  L.R. Pizzolato-Cezar, N.M. Okuda-Shinagawa, M.T. Machini, Front. Microbiol. 10 (2019) 1703. doi: 10.3389/fmicb.2019.01703
32. [32]
  C. R. Lincke, A.M. van der Bliek, G.J. Schuurhuis, et al., Cancer Res. 50 (1990) 1779-1785.
33. [33]
  J. Lehmann, M. Retz, S.S. Sidhu, et al., Eur. Urol. 50 (2006) 141-147. doi: 10.1016/j.eururo.2005.12.043
34. [34]
  P. Pandey, F. Khan, M.A. Khan, et al., Nutrients 15 (2023) 3111. doi: 10.3390/nu15143111
35. [35]
  M. Ke, J. Dong, Y. Wang, et al., Int. J. Biochem. Cell Biol. 101 (2018) 39-48. doi: 10.1016/j.biocel.2018.05.013
36. [36]
  X. Bai, J. Ni, J. Beretov, et al., Cancer Treat. Rev. 69 (2018) 152-163. doi: 10.1016/j.ctrv.2018.07.004
37. [37]
  C.H. Chen, Y.H. Liu, A. Eskandari, et al., Adv. Sci. 9 (2022) e2105506. doi: 10.1002/advs.202105506
38. [38]
  A.L. Hilchie, D.W. Hoskin, C.M. Power, Adv. Exp. Med. Biol. 1117 (2019) 131-147. doi: 10.1007/978-981-13-3588-4_9
39. [39]
  Y. Cong, L. Ji, Y.J. Gao, et al., Angew. Chem. Int. Ed. 58 (2019) 4632-4637. doi: 10.1002/anie.201900135
40. [40]
  T. Bahmani, S. Sharifzadeh, G. Tamaddon, et al., J. Biomed. Phys. Eng. 11 (2021) 229-238.
41. [41]
  L. Jiang, L. Li, X. He, et al., Biomaterials 52 (2015) 126-139. doi: 10.1016/j.biomaterials.2015.02.004
42. [42]
  X. Yan, Q. Yu, L. Guo, et al., ACS Appl. Mater. Interfaces 9 (2017) 6804-6815. doi: 10.1021/acsami.6b14244
43. [43]
  R.S. Li, J. Liu, H. Shi, et al., Nano Lett. 21 (2021) 8455-8465. doi: 10.1021/acs.nanolett.1c03112
44. [44]
  Y. Wen, X. Tan, X. Wu, et al., Cancer Biomark. 26 (2019) 21-30. doi: 10.3233/cbm-190096
45. [45]
  H. Zhou, A. Sauvat, L.C. Gomes-da-Silva, et al., Cell Death Differ. 23 (2016) 2031-2041. doi: 10.1038/cdd.2016.86
46. [46]
  B. Mauseth, K.A. Camilio, J. Shi, et al., Mol. Ther. Oncolytics 14 (2019) 139-148. doi: 10.1016/j.omto.2019.05.002
47. [47]
  A.P. Mutvei, M.J. Nagiec, J. Blenis, Nat. Cell Biol. 25 (2023) 1254-1264. doi: 10.1038/s41556-023-01197-7
48. [48]
  L. Wang, H. Zhu, Z. Shi, et al., Theranostics 14 (2024) 75-95. doi: 10.7150/thno.83051
49. [49]
  C.H. Hsu, K.J. Lee, Y.H. Chiu, et al., Cells 11 (2022) 1492. doi: 10.3390/cells11091492
50. [50]
  L. Zhang, S. Gui, Z. Liang, et al., Front. Microbiol. 10 (2019) 522. doi: 10.3389/fmicb.2019.00522
51. [51]
  J. Zeng, J. Wang, J. Wu, et al., J. Cell. Mol. Med. 27 (2023) 340-352. doi: 10.1111/jcmm.17644
52. [52]
  Y. Wu, D. Lu, Y. Jiang, et al., J. Med. Chem. 64 (2021) 5802-5815. doi: 10.1021/acs.jmedchem.0c02237
53. [53]
  Y. Li, X. Liu, X. Zhang, et al., Adv. Funct. Mater. 31 (2021) 2107540. doi: 10.1002/adfm.202107540
54. [54]
  J. Yang, C. Wang, S. Shi, et al., Nano Res. 13 (2020) 2595-2616. doi: 10.1007/s12274-020-2904-8
55. [55]
  Y. Wu, Z. Zhang, Y. Wei, Z. Qian, X. Wei, Chin. Chem. Lett. 34 (2023) 108098. doi: 10.1016/j.cclet.2022.108098
56. [56]
  Y. Xie, X. Li, J. Wu, et al., Chin. Chem. Lett. 34 (2023) 108202. doi: 10.1016/j.cclet.2023.108202
57. [57]
  X. Zhu, X. Wang, B. Li, et al., Small 18 (2022) e2107001. doi: 10.1002/smll.202107001
58. [58]
  B. Pahar, S. Madonna, A. Das, et al., Vaccines 8 (2020) 517. doi: 10.3390/vaccines8030517
59. [59]
  Z. Zhang, W.Q. Chen, S.Q. Zhang, et al., Front. Pharmacol. 13 (2022) 906625. doi: 10.3389/fphar.2022.906625
60. [60]
  J. Shin, B. Kim, T.W. Lager, et al., Nanoscale 15 (2023) 13322-13334. doi: 10.1039/d3nr00800b
61. [61]
  E. Heh, J. Allen, F. Ramirez, et al., Int. J. Mol. Sci. 24 (2023) 829. doi: 10.3390/ijms24010829
62. [62]
  Y. Zhang, T. Li, Y. Hu, et al., Chin. Chem. Lett. 33 (2022) 2507-2511. doi: 10.1016/j.cclet.2021.11.076
63. [63]
  N. Furukawa, A.S. Popel, Biochim. Biophys. Acta Rev. Cancer 1875 (2021) 188486. doi: 10.1016/j.bbcan.2020.188486
64. [64]
  M. Li, Y. Ning, J. Chen, et al., Nano Lett. 19 (2019) 7965-7976. doi: 10.1021/acs.nanolett.9b03136
65. [65]
  A. Thomas, B.A. Teicher, R. Hassan, Lancet Oncol. 17 (2016) e254-e262. doi: 10.1016/S1470-2045(16)30030-4
66. [66]
  F. Blackhall, K. Jao, L. Greillier, et al., J. Thorac. Oncol. 16 (2021) 1547-1558. doi: 10.1016/j.jtho.2021.02.009
67. [67]
  Y.S. Zhu, K. Tang, J. Lv, Trends Pharmacol. Sci. 42 (2021) 857-869. doi: 10.1016/j.tips.2021.07.001
68. [68]
  C. Fu, L. Yu, Y. Miao, et al., Acta Pharm. Sin. B 13 (2023) 498-516. doi: 10.1016/j.apsb.2022.07.020
69. [69]
  S. Liu, Y. Tian, S. Jiang, et al., Int. J. Mol. Sci. 24 (2023) 4590. doi: 10.3390/ijms24054590
70. [70]
  D. Kebebe, Y. Liu, Y. Wu, et al., Int. J. Nanomedicine 13 (2018) 1425-1442. doi: 10.2147/ijn.s156616
71. [71]
  B.R. Liu, Y.W. Huang, J.G. Winiarz, et al., Biomaterials 32 (2011) 3520-3537. doi: 10.1016/j.biomaterials.2011.01.041
72. [72]
  P.T. Gotora, R. van der Sluis, M.E. Williams, BMC Infect. Dis. 23 (2023) 164. doi: 10.1186/s12879-023-08123-0
73. [73]
  H. Wu, C. You, F. Chen, et al., Mater. Sci. Eng. C. Mater. Biol. Appl. 103 (2019) 109738. doi: 10.1016/j.msec.2019.109738
74. [74]
  M. Zorko, S. Jones, U. Langel, Adv. Drug Deliv. Rev. 180 (2022) 114044. doi: 10.1016/j.addr.2021.114044
75. [75]
  P. Hoppenz, S. Els-Heindl, A.G. Beck-Sickinger, Front. Chem. 8 (2020) 571. doi: 10.3389/fchem.2020.00571
76. [76]
  M. Finlayson, Front. Immunol. 6 (2015) 135.
77. [77]
  W. Gu, J. An, H. Meng, et al., Adv. Mater. 31 (2019) e1904742. doi: 10.1002/adma.201904742
78. [78]
  S.A. Ghamande, M.H. Silverman, W. Huh, et al., Gynecol. Oncol. 111 (2008) 89-94. doi: 10.1016/j.ygyno.2008.06.028
79. [79]
  F.L. Theodoulou, I.D. Kerr, Biochem. Soc. Trans. 43 (2015) 1033-1040. doi: 10.1042/BST20150139
80. [80]
  A. Alam, K.P. Locher. Annu. Rev. Biophys. 52 (2023) 275-300. doi: 10.1146/annurev-biophys-111622-091232
81. [81]
  X.D. Dong, M. Zhang, C.Y. Cai, et al., Front. Pharmacol. 13 (2022) 843829. doi: 10.3389/fphar.2022.843829
82. [82]
  K.K. To, D.C. Poon, Y. Wei, et al., Biochem. Pharmacol. 97 (2015) 27-37. doi: 10.1016/j.bcp.2015.06.034
83. [83]
  Y. Fan, T. Tao, Z. Guo, et al., Mol. Ther. Oncolytics 24 (2022) 636-649. doi: 10.1016/j.omto.2022.02.006
84. [84]
  K. Silbermann, J. Li, V. Namasivayam, et al., Eur. J. Med. Chem. 212 (2021) 113045. doi: 10.1016/j.ejmech.2020.113045
85. [85]
  C.D. Scripture, W.D. Figg, Nat. Rev. Cancer 6 (2006) 546-558. doi: 10.1038/nrc1887
86. [86]
  G. Szakacs, A. Varadi, C. Ozvegy-Laczka, et al., Drug Discov. Today 13 (2008) 379-393. doi: 10.1016/j.drudis.2007.12.010
87. [87]
  A. Adamska, M. Falasca, World J. Gastroenterol. 24 (2018) 3222-3238. doi: 10.3748/wjg.v24.i29.3222
88. [88]
  Q.X. Teng, X. Luo, Z.N. Lei, et al., Cancers 12 (2020) 1963. doi: 10.3390/cancers12071963
89. [89]
  X. Luo, Q.X. Teng, J.Y. Dong, et al., Front. Pharmacol. 11 (2020) 1208. doi: 10.3389/fphar.2020.01208
90. [90]
  H. Zhang, D. Han, T. Lv, et al., Drug Des. Devel. Ther. 13 (2019) 2153-2167. doi: 10.2147/dddt.s207224
91. [91]
  L.X. Shi, R. Ma, R. Lu, et al., Cancer Lett. 269 (2008) 101-110. doi: 10.1016/j.canlet.2008.04.033
92. [92]
  S. Rietwyk, D. Peer. ACS Nano 11 (2017) 7572-7586. doi: 10.1021/acsnano.7b04734
93. [93]
  W.Y. Tong, M. Alnakhli, R. Bhardwaj, et al., J. Nanobiotechnol. 16 (2018) 38. doi: 10.1186/s12951-018-0365-y
94. [94]
  J. Shu, X. Li, J. Dang, et al., Chem. Eng. J. (2021) 128545.
95. [95]
  D. Gupta, M. Kumar, P. Tyagi, et al., Nanomedicine 14 (2018) 1301-1313. doi: 10.1016/j.nano.2018.03.010
96. [96]
  I. Vitale, T. Yamazaki, E. Wennerberg, et al., Trends Cancer 7 (2021) 557-572. doi: 10.1016/j.trecan.2020.12.012
97. [97]
  S.Z. Shalhout, D.M. Miller, K.S. Emerick, et al., Nat. Rev. Clin. Oncol. 20 (2023) 160-177. doi: 10.1038/s41571-022-00719-w
98. [98]
  D. Lin, Y. Shen, T. Liang, Signal Transduct. Target. Ther. 8 (2023) 156. doi: 10.1038/s41392-023-01407-6
99. [99]
  T. Tang, X. Huang, G. Zhang, et al., J. Immunother. Cancer 10 (2022) e004129. doi: 10.1136/jitc-2021-004129
100. [100]
  J. Spicer, A. Marabelle, J.F. Baurain, et al., Clin. Cancer Res. 27 (2021) 2755-2763. doi: 10.1158/1078-0432.ccr-20-3435
101. [101]
  M. Nielsen, T. Monberg, V. Sundvold, et al., Oncoimmunology 13 (2024) 2290900. doi: 10.1080/2162402X.2023.2290900
102. [102]
  A. Kalbasi, A. Ribas, Nat. Rev. Immunol. 20 (2020) 25-39. doi: 10.1038/s41577-019-0218-4
103. [103]
  T. Yamazaki, J.M. Pitt, M. Vetizou, et al., Cell Death Differ. 23 (2016) 1004-1015. doi: 10.1038/cdd.2016.35
104. [104]
  L. Lu, H. Zhang, Y. Zhou, et al., Theranostics 12 (2022) 3456-3473. doi: 10.7150/thno.71129
105. [105]
  T. Tang, X. Huang, G. Zhang, et al., J. Immunother. Cancer 10 (2022) e005065. doi: 10.1136/jitc-2022-005065
106. [106]
  M. Alas, A. Saghaeidehkordi, K. Kaur, J. Med. Chem. 64 (2021) 216-232. doi: 10.1021/acs.jmedchem.0c01530
107. [107]
  M. Assadi, H. Ahmadzadehfar, World J. Nucl. Med. 18 (2019) 406-408. doi: 10.4103/wjnm.WJNM_112_18
108. [108]
  J.F. Nesari, K. Aryana, E. Askari, Clin. Nucl. Med. 46 (2021) e480-e482. doi: 10.1097/RLU.0000000000003685
109. [109]
  J.K. Jessee, Ann, Pharmacother. 56 (2022) 951-957. doi: 10.1177/10600280211058388
110. [110]
  S. Dhillon, Drugs 81 (2021) 963-969. doi: 10.1007/s40265-021-01522-0
111. [111]
  T. Olivier, V. Prasad, Transl. Oncol. 18 (2022) 101374. doi: 10.1016/j.tranon.2022.101374
112. [112]
  H. Zhang, S. Chen, RSC Chem. Biol. 3 (2022) 18-31. doi: 10.1039/D1CB00154J
113. [113]
  C. Morrison, Nat. Rev. Drug Discov. 17 (2018) 531-533. doi: 10.1038/nrd.2018.125
114. [114]
  M. Muttenthaler, G.F. King, D.J. Adams, et al., Nat. Rev. Drug Discov. 20 (2021) 309-325. doi: 10.1038/s41573-020-00135-8
115. [115]
  Y. Wu, Y. Zou, L. Sun, et al., Chin. Chem. Lett. 32 (2021) 4045-4048. doi: 10.1016/j.cclet.2021.04.030
116. [116]
  Y. Wu, M. Han, C. Liu, et al., RSC Adv. 7 (2017) 17514-17518. doi: 10.1039/C6RA26427A
117. [117]
  A. Kolate, D. Baradia, S. Patil, et al., J. Control. Release 192 (2014) 67-81. doi: 10.1016/j.jconrel.2014.06.046
118. [118]
  H. Lee, Pharmaceutics 12 (2020) 533. doi: 10.3390/pharmaceutics12060533
119. [119]
  A.E. Sanchez, A. Unterweger, F. Laffleur, Drug Dev. Ind. Pharm. 48 (2022) 129-139. doi: 10.1007/978-3-031-06539-2_7
120. [120]
  K. Ganesh, Z.K. Stadler, A. Cercek, et al., Nat. Rev. Gastroenterol. Hepatol. 16 (2019) 361-375. doi: 10.1038/s41575-019-0126-x
121. [121]
  H. Ren, R. Li, Z. Chen, et al., Chin. J. Org. Chem. 41 (2021) 3983-3994. doi: 10.6023/cjoc202104020
122. [122]
  Y. Wu, G. Xia, W. Zhang, et al., J. Mater. Chem. B 8 (2020) 9173-9196. doi: 10.1039/d0tb01916j
123. [123]
  J. Yang, H.W. An, H. Wang, ACS Appl. Bio Mater. 4 (2021) 24-46. doi: 10.1021/acsabm.0c00707
124. [124]
  S. Santini, N. Mousseau, P. Derreumaux, J. Am. Chem. Soc. 126 (2004) 11509-11516. doi: 10.1021/ja047286i
125. [125]
  H.W. An, M. Mamuti, X. Wang, et al., Exploration 1 (2021) 20210153. doi: 10.1002/EXP.20210153
126. [126]
  Z. Wang, H.W. An, D. Hou, et al., Adv. Mater. 31 (2019) e1807175. doi: 10.1002/adma.201807175
127. [127]
  L. Wang, C. Li, J. Wang, et al., Adv. Mater. 34 (2022) e2203518. doi: 10.1002/adma.202203518
128. [128]
  J. Yang, R. Zheng, M. Mamuti, et al., Biomaterials 284 (2022) 121488. doi: 10.1016/j.biomaterials.2022.121488
129. [129]
  H. Hamidi, J. Ivaska, Nat. Rev. Cancer 18 (2018) 533-548. doi: 10.1038/s41568-018-0038-z
130. [130]
  S. Naito, N. Sakamoto, S. Kotoh, et al., Eur. Urol. 24 (1993) 156-160. doi: 10.1159/000474284
131. [131]
  H.J. Han, J.Y. Sung, S.H. Kim, et al., Cancer Lett. 508 (2021) 59-72. doi: 10.1016/j.canlet.2021.03.011
132. [132]
  R.J. Motzer, N.H. Bander, D.M. Nanus, N. Engl. J. Med. 335 (1996) 865-875. doi: 10.1056/NEJM199609193351207
1. [1]
  Jiechen Liu , Xiaoguang Li , Ruiyang Xia , Yuqi Wang , Fenghe Zhang , Yongzhi Pang , Qing Li . Efficient suppression of oral squamous cell carcinoma through spatial dimension conversion drug delivery systems-enabled immunomodulatory-photodynamic therapy. Chinese Chemical Letters, 2024, 35(12): 109619-. doi: 10.1016/j.cclet.2024.109619
2. [2]
  Liangliang Jia , Ye Hong , Xinyu He , Ying Zhou , Liujiao Ren , Hongjun Du , Bin Zhao , Bin Qin , Zhe Yang , Di Gao . Fighting hypoxia to improve photodynamic therapy-driven immunotherapy: Alleviating, exploiting and disregarding. Chinese Chemical Letters, 2025, 36(2): 109957-. doi: 10.1016/j.cclet.2024.109957
3. [3]
  Shuang Liang , Jianjun Yao , Dan Liu , Mengli Zhou , Yong Cui , Zhaohui Wang . Tumor-responsive covalent organic polymeric nanoparticles enhancing STING activation for cancer immunotherapy. Chinese Chemical Letters, 2025, 36(3): 109856-. doi: 10.1016/j.cclet.2024.109856
4. [4]
  Yuequan Wang , Congtian Wu , Chengcheng Feng , Qin Chen , Zhonggui He , Shenwu Zhang , Cong Luo , Jin Sun . Spatiotemporally-controlled supramolecular hybrid nanoassembly enabling ferroptosis-augmented photodynamic immunotherapy of cancer. Chinese Chemical Letters, 2025, 36(3): 109902-. doi: 10.1016/j.cclet.2024.109902
5. [5]
  Ping Sun , Yuanqin Huang , Shunhong Chen , Xining Ma , Zhaokai Yang , Jian Wu . Indole derivatives as agrochemicals: An overview. Chinese Chemical Letters, 2024, 35(7): 109005-. doi: 10.1016/j.cclet.2023.109005
6. [6]
  Wei Sun , Anjing Liao , Li Lei , Xu Tang , Ya Wang , Jian Wu . Research progress on piperidine-containing compounds as agrochemicals. Chinese Chemical Letters, 2025, 36(1): 109855-. doi: 10.1016/j.cclet.2024.109855
7. [7]
  Chenlu Huang , Xinyu Yang , Qingyu Yu , Linhua Zhang , Dunwan Zhu . Gas-generating polymersomes-based amplified photoimmunotherapy for abscopal effect and tumor metastasis inhibition. Chinese Chemical Letters, 2024, 35(6): 109680-. doi: 10.1016/j.cclet.2024.109680
8. [8]
  Junjie Wang , Yan Wang , Zhengdong Li , Changqiang Xie , Musammir Khan , Xingzhou Peng , Fabiao Yu . Triphenylamine-AIEgens photoactive materials for cancer theranostics. Chinese Chemical Letters, 2024, 35(6): 108934-. doi: 10.1016/j.cclet.2023.108934
9. [9]
  Xinyue Lan , Junguang Liang , Churan Wen , Xiaolong Quan , Huimin Lin , Qinqin Xu , Peixian Chen , Guangyu Yao , Dan Zhou , Meng Yu . Photo-manipulated polyunsaturated fatty acid-doped liposomal hydrogel for flexible photoimmunotherapy. Chinese Chemical Letters, 2024, 35(4): 108616-. doi: 10.1016/j.cclet.2023.108616
10. [10]
  Bohan Chen , Liming Gong , Jing Feng , Mingji Jin , Liqing Chen , Zhonggao Gao , Wei Huang . Research advances of nanoparticles for CAR-T therapy in solid tumors. Chinese Chemical Letters, 2024, 35(9): 109432-. doi: 10.1016/j.cclet.2023.109432
11. [11]
  Peng Zhan . Practice and Reflection in Training Medicinal Chemistry Graduate Students. University Chemistry, 2024, 39(6): 112-121. doi: 10.3866/PKU.DXHX202402022
12. [12]
  Hongling Liu , Yue Xia , Guang Xu , Yafei Yang , Chunhua Qu . Bitter Cold Medicine, Good for Healing. University Chemistry, 2025, 40(3): 328-332. doi: 10.12461/PKU.DXHX202405039
13. [13]
  Shaoqing Du , Xinyong Liu , Xueping Hu , Peng Zhan . Targeting novel sites represents an effective strategy for combating drug resistance. Chinese Chemical Letters, 2025, 36(1): 110378-. doi: 10.1016/j.cclet.2024.110378
14. [14]
  Shuyu Liu , Xiaomin Sun , Bohan Song , Gaofeng Zeng , Bingbing Du , Chongshen Guo , Cong Wang , Lei Wang . Design and Fabrication of Phospholipid-Vesicle-based Artificial Cells towards Biomedical Applications. University Chemistry, 2024, 39(11): 182-188. doi: 10.12461/PKU.DXHX202404113
15. [15]
  Liping Zhao , Xixi Guo , Zhimeng Zhang , Xi Lu , Qingxuan Zeng , Tianyun Fan , Xintong Zhang , Fenbei Chen , Mengyi Xu , Min Yuan , Zhenjun Li , Jiandong Jiang , Jing Pang , Xuefu You , Yanxiang Wang , Danqing Song . Novel berberine derivatives as adjuvants in the battle against Acinetobacter baumannii: A promising strategy for combating multi-drug resistance. Chinese Chemical Letters, 2024, 35(10): 109506-. doi: 10.1016/j.cclet.2024.109506
16. [16]
  Chen Li , Ziyuan Zhao , Shouyun Yu . Photoredox-catalyzed C-glycosylation of peptides with glycosyl bromides. Chinese Chemical Letters, 2024, 35(6): 109128-. doi: 10.1016/j.cclet.2023.109128
17. [17]
  Wei Chen , Pieter Cnudde . A minireview to ketene chemistry in zeolite catalysis. Chinese Journal of Structural Chemistry, 2024, 43(11): 100412-100412. doi: 10.1016/j.cjsc.2024.100412
18. [18]
  Jing Zhang , Charles Wang , Yaoyao Zhang , Haining Xia , Yujuan Wang , Kun Ma , Junfeng Wang . Application of magnetotactic bacteria as engineering microrobots: Higher delivery efficiency of antitumor medicine. Chinese Chemical Letters, 2024, 35(10): 109420-. doi: 10.1016/j.cclet.2023.109420
19. [19]
  Di ZHANG , Tianxiang XIE , Xu HE , Wanyu WEI , Qi FAN , Jie QIAO , Gang JIN , Ningbo LI . Construction and antitumor activity of pH/GSH dual-responsive magnetic nanodrug. Chinese Journal of Inorganic Chemistry, 2025, 41(4): 786-796. doi: 10.11862/CJIC.20240329
20. [20]
  Yong-Dan Zhao , Yidan Wang , Rongrong Wang , Lina Chen , Hengtong Zuo , Xi Wang , Jihong Qiang , Geng Wang , Qingxia Li , Canqi Ping , Shuqiu Zhang , Hao Wang . Reversing artemisinin resistance by leveraging thermo-responsive nanoplatform to downregulating GSH. Chinese Chemical Letters, 2024, 35(6): 108929-. doi: 10.1016/j.cclet.2023.108929

Get Citation

PDF

XML

Metrics

PDF Downloads(3)
Abstract views(343)
HTML views(14)

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142